CAPOZIDE 50/25 Drug Patent Profile

Which patents cover Capozide 50/25, and when can generic versions of Capozide 50/25 launch?

Capozide 50/25 is a drug marketed by Apothecon and is included in one NDA.

The generic ingredient in CAPOZIDE 50/25 is captopril; hydrochlorothiazide. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the captopril; hydrochlorothiazide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Capozide 50/25

A generic version of CAPOZIDE 50/25 was approved as captopril; hydrochlorothiazide by RISING on December 29^th, 1997.

Summary for CAPOZIDE 50/25

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CAPOZIDE 50/25

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apothecon	CAPOZIDE 50/25	captopril; hydrochlorothiazide	TABLET;ORAL	018709-003	Oct 12, 1984		DISCN	Yes	No

International Patents for CAPOZIDE 50/25

See the table below for patents covering CAPOZIDE 50/25 around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	178115	PROCESS FOR PREPARING CYCLIC DEHYDRO-IMINO-ACIDS
Canada	1103255	PROLINE DERIVATIVES AND RELATED COMPOUNDS
United Kingdom	1564000
Philippines	14730	DERIVATIVES OF DEHYDROXYCLICIMINO ACIDS
Austria	365573
New Zealand	189574	DEHYDROCYCLICIMINO ACID DERIVATIVES PHARMACEUTICAL COMPOSITIONS

Summary:

Last updated: February 4, 2026

Capozide 50/25, a combination medication of captopril and hydrochlorothiazide, is used to treat hypertension. The drug’s patent status, market potential, competitive landscape, and manufacturing factors influence its investment outlook. This analysis examines these elements, evaluating risks and opportunities in the context of the current pharmaceutical environment.

---

What Are the Pharmaceutical Fundamentals of CAPOZIDE 50/25?

Active Ingredients & Formulation:

• Captopril (50 mg): An angiotensin-converting enzyme (ACE) inhibitor used to lower blood pressure.
• Hydrochlorothiazide (25 mg): A thiazide diuretic that reduces blood volume and pressure.

This fixed-dose combination aims to improve patient compliance by reducing pill burden compared to monotherapies.

Market Size & Growth:

• The global hypertension drug market was valued at approximately USD 26 billion in 2021.
• Expected CAGR of 3-4% through 2030, driven by aging populations and rising hypertension prevalence.

Product Lifecycle & Patent Status:

• Captopril was introduced in the late 1970s.
• Hydrochlorothiazide (HCTZ) has been in use since the 1950s.
• Patent expiration for many ACE inhibitors and thiazides occurred in the early 2000s.
• Capozide 50/25's original patent likely expired or is close to expiry, reducing exclusivity.

Regulatory Environment:

• Approved by the FDA; compliance with ANDA (Abbreviated New Drug Application) regulations.
• Potential for generic competition post-patent expiry.

Manufacturing & Supply Chain:

• Captopril synthesis involves complex processes, but generic manufacturing is well-established.
• Hydrochlorothiazide production is mature, with multiple global suppliers.
• Stability and shelf life are well documented, supporting worldwide distribution.

---

What Are the Investment Opportunities and Risks?

Competitive Landscape:

• Market dominated by generics; original manufacturer faces intense price competition.
• Several generic versions available, often priced 40-60% lower than branded formulations.
• Limited differentiation due to similar efficacy and safety profiles among competitors.

Pricing & Reimbursement:

• Pricing pressure from health agencies and insurance providers.
• Reimbursement policies favor low-cost generics, reducing profit margins.

Market Penetration Strategies:

• Branding efforts focus on physician and patient familiarity.
• Potential for niche positioning in treatment-resistant hypertensive populations if clinical data support superior outcomes.

Legal & Patent Risks:

• Patent expiry exposes the product to generic entry.
• Risk of patent litigation if patent protections are still active or if formulation patents are maintained.

Regulatory & Compliance Risks:

• Changes in regulatory standards could impact approval status or registration.
• Quality standards compliance can add costs, especially in emerging markets.

R&D & Innovation Prospects:

• No current evidence suggesting significant pipeline modifications.
• Opportunities include developing extended-release formulations or combination with novel agents.

---

Financial & Commercial Assessment:

Aspect	Details
Market share (current)	Low, due to widespread generic availability
Pricing (average)	USD 3-8 per pill depending on region; significantly lower than branded products
Gross margins	Marginal due to high competition; estimated at 10-20% for generics
R&D costs for reformulation	High, with uncertain ROI; minimal incentive without innovation
Regulatory hurdles	Low for existing formulations; higher for new or modified versions

---

Key Challenges & Opportunities

• Challenges: Intense price competition, patent expiration, limited differentiation, regulatory shifts.
• Opportunities: Expansion into emerging markets, combination with other antihypertensives, patient adherence programs.

---

Key Takeaways:

• The product is mature, with limited patent protections, facing pricing and market share pressures.
• Investment returns depend on niche positioning, operational efficiency, and geographic expansion.
• The core strength lies in the established efficacy and safety profiles, but commoditization limits upside.
• Substantial barriers exist for innovation unless new formulations or delivery methods are developed.
• Entry into emerging markets can mitigate Western market pressures but involves regulatory and infrastructural challenges.

---

FAQs

1. What is the patent status of CAPOZIDE 50/25?
Most patents covering initial formulation or specific dose combinations have expired or are close to expiry, exposing the product to generic competition.

2. How does market competition affect investment prospects?
Intense generic competition drives prices down, reduces margins, and limits growth unless differentiating features are introduced.

3. Are there regulatory hurdles for expanding CAPOZIDE’s use?
Regulatory hurdles are minimal for existing formulations but increase if reformulation or new indications are pursued. Regulatory standards vary by region.

4. What is the potential for unmet medical needs?
Limited. Fixed-dose combination is established, and most hypertensive patients are adequately managed with existing therapies.

5. Can manufacturing scale improve profitability?
Yes. Cost efficiencies and supply chain optimization can improve margins, especially in high-volume markets.

---

Citations

1. Grand View Research. Hypertension Drugs Market Size, Share & Trends Analysis Report, 2022-2030.
2. U.S. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
3. IQVIA. Global Pharmaceutical Market Reports, 2021-2022.
4. Perrone, et al. "Generic Drugs: Price Competition and Market Dynamics." Health Economics Review, 2020.
5. European Medicines Agency. Market Authorization Reports, 2022.